drugset / Trial / NCT05336695
Assess Fibrin in Brains With AD/ADRD
Phase 1/2
Recruiting
30 enrolled
Massachusetts General Hospital
National Heart, Lung, and Blood Institute (NHLBI) · collab
NaSingle-groupOpen-labelDiagnostic
Summary
The goal of this project is to quantify brain fibrin content using 64Cu-FBP8-PET in the brains of subjects ranging from cognitively normal to clinically diagnosed with ADRD to evaluate potential regional differences.
Timeline
- Start
- 2022-03-29
- Primary completion
- 2026-09-28
- Completion
- 2026-09-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 64Cu-FBP8 | Diagnostic / imaging agent | — | Intravenous |